For Immediate Release
Chicago, IL – November 30, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: McDonald's Corporation (
MCD Quick Quote MCD - Free Report) , Amgen Inc. ( AMGN Quick Quote AMGN - Free Report) , NextEra Energy, Inc. ( NEE Quick Quote NEE - Free Report) , General Mills, Inc. ( GIS Quick Quote GIS - Free Report) and Take-Two Interactive Software, Inc. ( TTWO Quick Quote TTWO - Free Report) . Here are highlights from Wednesday’s Analyst Blog: Top Stock Reports for McDonald's, Amgen and NextEra
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including McDonald's Corporation, Amgen Inc. and NextEra Energy, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>> McDonald's shares have performed roughly in-line with the Zacks Retail - Restaurants industry this year (+6.4% vs. +6.2%). The company’s top and the bottom line increased on a year-over-year basis in the last quarterly report on October 30th. Robust comparable sales, menu price increase and positive guest counts backed the upside. Also, its emphasis on digital initiatives, campaigns and loyalty programs bodes well. During the quarter, digital sales came in at $9 billion, contributing 40% to the company’s system-wide sales. Given the rise in digital adoption, the company remains optimistic and anticipates the initiatives to drive sales and average checks in the upcoming periods. Earnings estimates for 2023 have increased in the past 30 days, depicting analysts’ optimism. However, inflationary pressures and stiff competition are primary headwinds. (You can ) read the full research report on McDonald’s here >>> Shares of Amgen have outperformed the Zacks Medical - Biomedical and Genetics industry over the year-to-date basis (+4.6% vs. -22.9%). The company expects strong sales growth of products like Tezspire, Evenity, Repatha, Prolia and Tavneos to be offset by lower revenues from oncology biosimilars and legacy established products such as Enbrel in the future quarters. The recently completed acquisition of Horizon Therapeutics is expected to enhance Amgen’s growth prospects. Amgen also has some key pipeline assets in obesity and inflammation, which are indications that can have a large market opportunity. Several data readouts are expected in the next 12 months. However, increased pricing headwinds and competitive pressure are hurting sales of many of Amgen’s products, including some biosimilars. Weakness in some key brands like Otezla and Lumakras create potential revenue headwinds. (You can ) read the full research report on Amgen here >>> Shares of NextEra Energy have underperformed the Zacks Utility - Electric Power industry over the year-to-date basis (-28.5% vs. -9.5%). Due to the company’s nature of its business, it is subject to complex regulations. Risks in operating nuclear units, unfavorable weather conditions and increasing supply costs adversely impact earnings. Nevertheless, NextEra Energy continues to expand its operations through organic projects and acquisitions. The company has many renewable projects in its backlog and continues to enhance its renewable energy generation capacity. NextEra’s subsidiary FPL’s customer base is expanding as Florida’s economy improves. The company has ample liquidity to meet its near-term debt obligations. It is expanding its operations in the water space through acquisitions. NextEra Energy decided to sell its gas assets in Florida to focus on its core business. (You can ) read the full research report on NextEra Energy here >>> Other noteworthy reports we are featuring today include General Mills, Inc. and Take-Two Interactive Software, Inc. Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of
+46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation. See Stocks Free >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.